Diakonos Oncology Revenue and Competitors
Employee Data
- Diakonos Oncology has 9 Employees.
- Diakonos Oncology grew their employee count by -10% last year.
Diakonos Oncology's People
| Name | Title | Email/Phone |
|---|
Diakonos Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $16.1M | 77 | 17% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $10.1M | 50 | 6% | N/A | N/A |
#6 | $119.4M | 757 | 38% | $50M | N/A |
#7 | $22.9M | 114 | 8% | N/A | N/A |
#8 | $92.9M | 462 | 8% | N/A | N/A |
#9 | $11.3M | 51 | 11% | N/A | N/A |
#10 | $7M | 33 | 14% | N/A | N/A |
What Is Diakonos Oncology?
Diakonos Oncology is pioneering cancer treatment with DOC1021, an FDA Fast Track-designated \double-loaded\ dendritic cell therapy for glioblastoma (GBM) and pancreatic cancer (PDAC). This personalized, autologous therapy has shown exceptional safety and efficacy, achieving an 88% 12-month survival rate in unmethylated GBM Phase I trials, with 38% of patients still alive after 18–29 months. With a Phase II trial launching in Q1 2025 at top GBM centers nationwide, Diakonos is reshaping outcomes for patients with the most challenging cancers.
keywords:N/A
N/A
Total Funding
9
Number of Employees
N/A
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $1.1M | 9 | N/A | N/A |
#4 | $1.1M | 9 | N/A | N/A |
#5 | $2.6M | 9 | -10% | N/A |